NTRA

Natera Inc

Add to Watchlist

Advanced Chart

198.230

-0.7(-0.352%)1D

Line

Candle

YTD

High

200.760

Open

198.710

VWAP

197.64

Vol

1.64M

Mkt Cap

27.21B

Low

194.070

Amount

323.52M

EV/EBITDA(TTM)

Total Shares

122.80M

26.27B

EV/OCF(TTM)

140.70

P/S(TTM)

13.33

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

575.92M

+14.76%

-0.344

-31.11%

532.90M

+11.94%

-0.356

-13.25%

514.78M

+17.06%

-0.371

+42.68%

Estimates Revision

The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 2.78% over the past three months. During the same period, the stock price has changed by 45.15%.

Revenue Estimates for FY2025

Revise Upward

+2.78%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-7.86%

In Past 3 Month

Stock Price

Go Up

+45.15%

In Past 3 Month

18 Analyst Rating

3.67% Upside

Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 205.50 USD with a low forecast of 172.00 USD and a high forecast of 268.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

2 Hold

0 Sell

Strong Buy

3.67% Upside

Current: 198.230

Low

172.00

Averages

205.50

High

268.00

3.67% Upside

Current: 198.230

Low

172.00

Averages

205.50

High

268.00

BNP Paribas Exane

Navann Ty

Underperform

Neutral

upgrade

$172

2025-10-27

Reason

BNP Paribas Exane

Navann Ty

Price Target

$172

2025-10-27

upgrade

Underperform

Neutral

Reason

BNP Paribas Exane analyst Navann Ty upgraded Natera to Neutral from Underperform with a $172 price target.

BTIG

Mark Massaro

Buy

maintain

$200 -> $210

2025-10-23

Reason

BTIG

Mark Massaro

Price Target

$200 -> $210

2025-10-23

maintain

Buy

Reason

BTIG analyst Mark Massaro raised the firm's price target on Natera to $2 10 from $200 and keeps a Buy rating on the shares. The firm is positive on Natera following the company's call with the lead principal investigator of the IMvigor011 trial, a randomized, double-blind, phase III study in muscle-invasive bladder cancer. The study was recently presented in a Presidential Symposium at ESMO in Berlin, Germany, and published in the New England Journal of Medicine. BTIG says ESMO studies may elevate the company's Signatera and the MRD field to a new level, and that it expects clinician and biopharma activity to pick up from here. Natera remains a Top Pick, the firm adds.

Wells Fargo

Brandon Couillard

Equal Weight

initiated

$175

2025-09-22

Reason

Wells Fargo

Brandon Couillard

Price Target

$175

2025-09-22

initiated

Equal Weight

Reason

Wells Fargo analyst Brandon Couillard initiated coverage of Natera with an Equal Weight rating and $175 price target. The firm's enthusiasm for Signatera's growth potential in molecular residual disease is offset by less conviction in Natera's margin and cash flow outlook. Trading at 10-times revenue, Natera's valuation implies a rich multiple for oncology, the analyst tells investors in a research note. Wells tells investors to wait for a better entry point.

RBC Capital

Conor McNamara

Outperform

maintain

$255 -> $268

2025-09-02

Reason

RBC Capital

Conor McNamara

Price Target

$255 -> $268

2025-09-02

maintain

Outperform

Reason

RBC Capital analyst Conor McNamara raised the firm's price target on Natera to $268 from $255 and keeps an Outperform rating on the shares as part of a broader research note on the Life Sciences Tools and Diagnostics sector. The firm is updating its model with "more realistic" multiples, the analyst tells investors in a research note. RBC added however that Natera is the market leader in liquid biopsy testing, with #1 positions in a $30B TAM that includes noninvasive prenatal testing and minimal residual disease, with potential future launches into the market-doubling opportunity of cancer screening. Additional test approvals in current markets, and a potential near-term launch in Natera's biggest market opportunity, all give the company multiple avenues to continue to grow revenues in double digits for the sustainable future, RBC stated.

Piper Sandler

NULL -> Overweight

maintain

$210 -> $220

2025-08-11

Reason

Piper Sandler

Price Target

$210 -> $220

2025-08-11

maintain

NULL -> Overweight

Reason

Piper Sandler raised the firm's price target on Natera to $220 from $210 following quarterly results. The firm keeps an Overweight rating on the shares.

Canaccord

Buy

maintain

$195 -> $200

2025-08-11

Reason

Canaccord

Price Target

$195 -> $200

2025-08-11

maintain

Buy

Reason

Canaccord raised the firm's price target on Natera to $200 from $195 and keeps a Buy rating on the shares. The firm said the stock remains a focus pick in their coverage universe after a strong 2Q beat and announcements of multiple efforts that should drive incremental growth. The price target increase is driven by raised estimates following its impressive 2Q update.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Natera Inc (NTRA.O) is -138.81, compared to its 5-year average forward P/E of -37.54. For a more detailed relative valuation and DCF analysis to assess Natera Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-37.54

Current PE

-138.81

Overvalued PE

-3.59

Undervalued PE

-71.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-38.42

Current EV/EBITDA

-178.62

Overvalued EV/EBITDA

-1.94

Undervalued EV/EBITDA

-74.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

9.82

Current PS

198.93

Overvalued PS

22.24

Undervalued PS

-2.60